| Texto completo | |
| Autor(es): |
Maurilio de Souza Cazarim
[1]
;
João Paulo Vilela Rodrigues
[2]
;
Priscila Santos Calcini
[3]
;
Thomas R. Einarson
[4]
;
Leonardo Régis Leira Pereira
[5]
Número total de Autores: 5
|
| Afiliação do(s) autor(es): | [1] Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto - Brasil
[2] Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto - Brasil
[3] Universidade de Ribeirão Preto. Faculdade de Ciências Farmacêuticas - Brasil
[4] University of Toronto. Leslie Dan Faculty of Pharmacy - Canadá
[5] Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto - Brasil
Número total de Afiliações: 5
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Revista de Saúde Pública; v. 54, 2020-09-30. |
| Resumo | |
ABSTRACT OBJECTIVE: To perform a cost-benefits analysis of a clinical pharmacy (CP) service implemented in a Neurology ward of a tertiary teaching hospital. METHODS: This is a cost-benefit analysis of a single arm, prospective cohort study performed at the adult Neurology Unit over 36 months, which has evaluated the results of a CP service from a hospital and Public Health System (PHS) perspective. The interventions were classified into 14 categories and the costs identified as direct medical costs. The results were analyzed by the total and marginal cost, the benefit-cost ratio (BCR) and the net benefit (NB). RESULTS: The total 334 patients were followed-up and the highest occurrence in 506 interventions was drug introduction (29.0%). The marginal cost for the hospital and avoided cost for PHS was US$182±32 and US$25,536±4,923 per year; and US$0.55 and US$76.4 per patient/year. The BCR and NB were 0.0, -US$26,105 (95%CI −31,850 − –10,610), -US$27,112 (95%CI −33,160–11,720) for the hospital and; 3.0 (95%CI 1.97–4.94), US$51,048 (95%CI 27,645–75,716) and, 4.6 (95%CI 2.24–10.05), US$91,496 (95%CI 34,700–168,050; p < 0.001) for the PHS, both considering adhered and total interventions, respectively. CONCLUSIONS: The CP service was not directly cost-benefit at the hospital perspective, but it presented savings for forecast cost related to the occurrence of preventable morbidities, measuring a good cost-benefit for the PHS. (AU) | |
| Processo FAPESP: | 16/03584-1 - Desenvolvimento e validação de uma ferramenta farmacoeconômica para a implantação da atenção farmacêutica para pacientes hipertensos no sistema público de saúde do brasil |
| Beneficiário: | Maurilio de Souza Cazarim |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado |
| Processo FAPESP: | 17/21240-0 - Desenvolvimento e validação de uma ferramenta farmacoeconômica para tomada de decisão na implantação da atenção farmacêutica para pacientes hipertensos no sistema de saúde público |
| Beneficiário: | Maurilio de Souza Cazarim |
| Modalidade de apoio: | Bolsas no Exterior - Estágio de Pesquisa - Doutorado |